Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study
Clemente Díaz(University of Puerto Rico System), Stephen J. Thomas(Walter Reed Army Institute of Research), Rafael De La Barrera(Walter Reed Army Institute of Research), Maribel Campos(University of Puerto Rico System), Luis Javier Martínez-González(Walter Reed Army Institute of Research), Kenneth H. Eckels(Walter Reed Army Institute of Research), Robert Paris(GlaxoSmithKline (United States)), Richard G. Jarman(Walter Reed Army Institute of Research), Edith Lepine(GlaxoSmithKline (United States)), David W. Vaughn(Armed Forces Research Institute of Medical Science), Michael Koren(Jacksonville University), Alexander C. Schmidt(GlaxoSmithKline (United States)), Todd M. Wilson(National Institutes of Health), Leyi Lin(Walter Reed Army Institute of Research), Irma Febo(University of Puerto Rico System)
Cited by 15
Related Papers
Neurological manifestations of dengue infection
|The Lancet|2000|637
Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number
|Nature Genetics|2016|393
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
|New England Journal of Medicine|2015|390